The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation
Author(s) -
Jennifer J. Westendorf,
Cindy M. Yamamoto,
Noel Lenny,
James R. Downing,
Michael E. Selsted,
Scott W. Hiebert
Publication year - 1998
Publication title -
molecular and cellular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.14
H-Index - 327
eISSN - 1067-8824
pISSN - 0270-7306
DOI - 10.1128/mcb.18.1.322
Subject(s) - transactivation , biology , transcription factor , microbiology and biotechnology , core binding factor , transcription (linguistics) , promoter , enhancer , ccaat enhancer binding proteins , myeloid leukemia , cancer research , dna binding protein , gene , gene expression , genetics , linguistics , philosophy
AML-1B is a hematopoietic transcription factor that is functionally inactivated by multiple chromosomal translocations in human acute myeloblastic and B-cell lymphocytic leukemias. The t(8;21)(q22;q22) translocation replaces the C terminus, including the transactivation domain of AML-1B, with ETO, a nuclear protein of unknown function. We previously showed that AML-1–ETO is a dominant inhibitor of AML-1B-dependent transcriptional activation. Here we demonstrate that AML-1–ETO also inhibits C/EBP-α-dependent activation of the myeloid cell-specific, rat defensin NP-3 promoter. AML-1B bound the core enhancer motifs present in the NP-3 promoter and activated transcription approximately sixfold. Similarly, C/EBP-α bound NP-3 promoter sequences and activated transcription approximately sixfold. Coexpression of C/EBP-α with AML-1B or its family members, AML-2 and murine AML-3, synergistically activated the NP-3 promoter up to 60-fold. The t(8;21) product, AML-1–ETO, repressed AML-1B-dependent activation of NP-3 and completely inhibited C/EBP-α-dependent activity as well as the synergistic activation. In contrast, theinv(16) product, which indirectly targets AML family members by fusing their heterodimeric DNA binding partner, CBF-β, to the myosin heavy chain, inhibited AML-1B but not C/EBP-α activation or the synergistic activation. AML-1–ETO and C/EBP-α were coimmunoprecipitated and thus physically interact in vivo. Deletion mutants demonstrated that the C terminus of ETO was required for AML-1–ETO-mediated repression of the synergistic activation but not for association with C/EBP-α. Finally, overexpression of AML-1–ETO in myeloid progenitor cells prevented granulocyte colony-stimulating factor-induced differentiation. Thus, AML-1–ETO may contribute to leukemogenesis by specifically inhibiting C/EBP-α- and AML-1B-dependent activation of myeloid promoters and blocking differentiation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom